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Creating functional autogenous vascular access in
older patients
William C. Jennings, MD,a Lesley Landis, MD,a Kevin E. Taubman, MD,a and
Donald E. Parker, PhD,b Tulsa, Okla
Objective: Arteriovenous fistulas (AVFs) are the preferred choice for hemodialysis vascular access (AV access); however,
there is debate over the utility of AVFs in older patients, particularly concerning access maturation and functionality. We
reviewed our AV access experience in patients >65 years of age.
Methods: We analyzed consecutive AV access patients >65 years old with access operations between March 2003 and
December 2009. All patients had ultrasound vessel mapping. In addition to overall outcomes review, the data for patients
>65 years old were stratified into three 10-year increments by age for further analysis. We compared functional patency
data for our older patients with those of our non-elderly patients aged 21 to 64 years treated during the same time period.
Results: Four hundred sixty-one consecutive AV access patients new to our practice were included in this study. Ages were
65 to 94 years (mean, 73 years). Two hundred thirty-six (51.2%) were female, 276 (59.9%) patients were diabetic, and
103 (22.3%) were obese. One hundred seven (23.2%) patients had previous access operations. Radiocephalic AVFs were
constructed in 29 (6.3%) patients, 99 (21.5%) patients had brachial artery inflow AVFs, 330 (71.6%) had proximal radial
artery AVFs, and three were based on the femoral artery. Transposition AVFs were used in 124 (26.9%) patients. No
grafts were used for AV access in any patient during the study period. Time to AVF use was 0.5 to 6 months (mean, 1.5
months). Primary, primary assisted, and cumulative patency for patients aged 65 to 94 years were 59.9%, 93.7%, and
96.9% at 12 months and 45.3%, 90.1%, and 94.6% at 24 months, respectively. Follow-up was 1.5 to 77 months (mean,
17.0months). Subgroup age stratification (65-74 [n 268], 75-84 [n 167], 85-94 [n 26] years) found no statistical
difference in functional access outcomes. Primary, primary assisted, and cumulative patency rates were not statistically
different in the elderly and non-elderly populations (P  .29, .27, and .37, respectively). One hundred fifty-six patients
died during the study period, 1.3 to 61 months (mean, 20 months) after access creation. No deaths were related to access
operations.
Conclusions: AVFs are feasible and offer functional and timely AV access in older patients. There was no difference in
functional access outcomes for older patients with subgroup age stratification. AVF patency rates were not statistically
different in the elderly and non-elderly populations. Cumulative AVF patency for patients>65 years of age was 96.9% at
12 months and 94.6% at 24 months. (J Vasc Surg 2011;53:713-9.)
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oThe National Institute on Aging reports that the
United States population aged 65 and over is expected to
double in size within the next 25 years. By 2030, more than
70 million people will be 65 years or older. The age group
85 and older is now the fastest growing segment of theU.S.
population.1 The incidence of chronic kidney disease and
renal replacement therapy (RRT) are similarly increasing in
older individuals and at a higher rate than for the non-
elderly population, accounting for most of the increase.2-4
Vascular access for hemodialysis (HD) using an arterio-
venous fistula (AVF) is widely regarded as superior to
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doi:10.1016/j.jvs.2010.09.057atheters (CVC) and grafts (AVG) in morbidity, mortality,
nd overall cost evaluations.5-10 However, the use of au-
ogenous access in the elderly population is the subject of
ebate, particularly with regard to the issues of timely
ccess maturation and primary AVF failure rates. Successful
VF outcomes have been reported by some investigators
hile other authors found less than satisfactory results.11-20
ife expectancy and quality of life issues are key elements in
his discussion. This study reviews our experience providing
utogenous vascular access for older patients.
ETHODS
We reviewed our database of consecutive patients new
o our practice referred for HD access fromMarch 2003 to
ecember 2009, identifying all individuals 65 years of age
nd older. We compared primary, primary assisted, and
umulative vascular access patency rates for these patients
ersus our non-elderly patients aged 21 to 64 years treated
uring the same time period. In addition, we analyzed
hese data for patients 65 years old stratified into three
roups of patients with ages in 10-year segments (Group
 65-74 years, Group 2 75-84 years, Group 3 84-95
ears). Survival rates were calculated for patients65 years
f age in addition to survival analysis of the same three
ubgroups.
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March 2011714 Jennings et alAll patients underwent ultrasound vessel mapping by
the operating surgeon at the initial consultation along with
physical examination.20 Our general sequence of choice for
vascular access operations has been the same for all age
groups: 1) Radiocephalic AVFs (RC-AVF) when feasible.
2) Mid-arm AVFs, based on the proximal radial artery for
inflow when possible.22 3) Staged or primary transposition
AVFs.21,23 The basilic vein was the preferred conduit;
however, the brachial vein offered an acceptable alterna-
tive.24 4) Other options were used infrequently including
vein translocations, femoral vein AVFs, or saphenous vein
AVFs. The ultrasound (US) examination was a key compo-
nent in selecting the best site and vessels for these AVF
options. We find that many older patients have thinning
and fragile forearm skin and soft tissue in addition to years
of forearm intravenous access and venipunctures. We feel
selecting the upper arm cephalic vein as the targeted AVF
outflow vein leads to prompt maturation and successful
cannulation in most of these patients. Our requirement for
minimal outflow vein diameter was 2.5 mm with a tourni-
quet in place, and an arterial diameter of 2.0 mm. US was
used again briefly in the operating suite to confirm the
targeted outflow vein and surgical plan.
All patients were followed in the surgical clinic until the
new vascular access was fully functional for dialysis, using
two needles for repeated HD without use of a catheter.
Ultrasound was routinely used in addition to physical ex-
amination to evaluate AVF flow volume, vein size and
location, and for marking the targeted outflow location
prior to the first use of the access. Our general criteria for
initial cannulation 4 to 6 weeks after access creation was
flow volume by US400 mL/min and outflow vein diam-
eter 6 mm. For stage 4 chronic kidney disease (pre-
dialysis) patients, we considered the access “ready for use”
when it met these requirements. These individuals were
included in the data analysis as functionally patent if they
met the above criteria.
No monitoring protocol was in place; however, prob-
lems such as recirculation, inadequate inflow, high venous
pressures, or prolonged cannulation site bleeding lead to a
surgical evaluation for physical and US examinations fol-
lowed by a fistulogram and intervention as indicated. But-
tonhole (same site cannulation) access technique was en-
couraged, particularly in transposition AVFs and in those
AVFs with shorter cannulation segments.25 All patients
referred with failed or failing AVGs were evaluated for
conversion to a secondary AVF.26 Patients with mild symp-
toms of steal syndrome but without motor deficit, rest pain,
ulceration, or threatened tissue loss were monitored in our
clinic without intervention. Physical examination with
pulse volume recordings, finger pressures, digital/brachial
indexes, pulse oximetry, and access flow measurements
were used for evaluation and treatment planning in severely
symptomatic individuals with arteriography added if inter-
vention was necessary.
Primary patency was defined as the time (months) with
uninterrupted patency and without intervention. Primary
assisted patency was the time of uninterrupted patency drom the original AVF construction where any interven-
ional procedure was necessary. Cumulative (secondary)
atency was the period from the original AVF construction
here AVF patency was interrupted by thrombosis, with or
ithout AVF salvage, until abandonment of the access or
ntil completion of the study period. Patency in this study
efers to a functional access. It is our practice to construct
n autogenous vascular access for every patient.
Statistical analysis was performed using NCSS software
NCSS Statistical Software, Kaysville, Utah) with signifi-
ance of differences determined at P .05. P values were
btained by Cox multivariate regression analysis. Patients
enerally received systemic heparinization during the pro-
edures. Neither prophylactic antibiotics nor any form of
ostoperative anticoagulation were used in our patients.
nesthesia was provided by sedation with local infiltration
nd the addition of regional block administered by the
urgeon through the axillary portion of the incision for
ransposition procedures. The operations were performed
n an outpatient basis at a university-affiliated tertiary med-
cal center by the communicating author. CV8 Gore Tex
Gore & Associates, Newark, Del) suture was used for each
ascular anastomosis. This study was approved by our In-
titutional Review Board.
ESULTS
We identified 461 consecutive patients new to our
ractice aged 65 years and older who had a permanent
ascular access created for HD from May 2003 to Decem-
er 2009. The mean age was 73 years (range, 65-94 years).
iabetes was the cause of renal failure in 276 (59.9%)
ndividuals. Female gender accounted for 236 (51.2%)
atients, and 107 (23.2%) individuals had previous vascular
ccess operations. Medical records identified 103 (22.3%)
atients as obese.
During the same study period, 618 patients new to our
ractice aged 21 to 64 years (mean, 53 years) had a perma-
ent vascular access created for HD, and functional access
atency rates for these individuals were compared with our
atients aged 65 years and older. Diabetes was listed as the
ause of renal failure in 348 (56.3%) of these patients, with
94 (47.6%) females and 221 (35.8%) with previous vascu-
ar access operations. Obesity was noted in 170 (27.5%) of
hese patients.
Primary, primary assisted, and cumulative patency rates
ere not statistically different in the elderly and non-elderly
opulations (P  .29, .27, and .37, respectively) and are
hown in Figs 1, A-C. Multivariate analysis using Cox
egression found no statistical difference between those
ndividuals aged 21 to 64 years and patients aged 65 years
nd older in primary, primary assisted, and cumulative
atency rates (P  .19, .24, and .51, respectively), after
djustment for obesity, diabetes, and gender. Multivariate
nalysis using Cox regression for patients 65 years of age
ound the risk for primary access failure higher for females
1.35 risk ratio, P  .01) and approached significance for
besity (P  .08). No statistical difference was found for
iabetic patients. The risk for assisted (intervention re-
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Volume 53, Number 3 Jennings et al 715uired) access failure was higher for females (1.95 risk ratio,
 .01) and in obese patients (1.59 risk ratio, P  .02),
ith no statistical difference found in diabetic patients. The
isk for cumulative (secondary) access failure was higher for
emales (2.31 risk ratio, P  .02) and in obese individuals
2.01 risk ratio, P .05). There was no statistical difference
or diabetic patients. Primary, primary assisted, and cumu-
ative patency rates were not different for the three elderly
atient age subgroups (P .37, .38, and .37, respectively).
rimary, primary assisted, and cumulative patency for pa-
ients aged 65 to 94 years were 59.9%, 93.7%, and 96.9% at
2 months and 45.3%, 90.1%, and 94.6% at 24 months,
espectively.
Overall patient survival for individuals aged 65 to 94
ears of age was 86.0% at 12 months and 52.7% at 24
onths (Fig 2,A). Survival for these older patients was not
elated to gender (P  .33) or obesity (P  .54), although
pproached significance for diabetic patients (P  .09).
mong the three subgroups of older patients after adjust-
ent for diabetes, gender, and obesity, there was a signifi-
ant difference (P .041) in survival between groups, with
roup 3 (the oldest patients) found to have shorter survival,
s would be expected (Fig 2, B).
Simple AVFs were constructed in 337 (73.1%) patients.
f these, 29 were radiocephalic (wrist) AVFs, 53 brachial-
ephalic AVFs, and 255 were proximal radial artery AVFs
PRA-AVFs). Transposition AVFs were used in 124
26.9%) patients. Of these, 79 transpositions used the
asilic vein, 35 used the brachial vein, and six used the
ephalic vein. The femoral and saphenous veins were each
sed twice. Fifty-two AVF transpositions were created as
rimary procedures and 72 were staged. Twelve patients
equired a surgical AVF revision after a fistulogram and
ailed attempt at percutaneous intervention. All other ac-
ess interventions for maturation or maintenance were
ccomplished with a diagnostic fistulogram and balloon
ngioplasty as indicated. Mean follow-up was 17.0 months
range, 1.5-77.0 months). Three patients were admitted to
he hospital for hematomas with cellulitis that resolved
ithout surgical intervention. One patient had a wound
eparation that was closed surgically. No deaths were re-
ated to vascular access operations. Six patients regained
enal function, discontinuing dialysis. They were not cen-
ig 1. A, Kaplan-Meier vascular access patency curves. Number
t risk indicated along curves. Primary arteriovenous fistula (AVF)
atency was not different in the elderly versus non-elderly popula-
ions (P  .29). Dotted lines are used to indicate when patient
umbers were lower and the curves become imprecise.
, Kaplan-Meier vascular access patency curves. Number at risk
ndicated along curves. Assisted AVF patency was not different in
he elderly versus non-elderly populations (P  .27). Dotted lines
re used to indicate when patient numbers were lower and the
urves become imprecise. C, Kaplan-Meier vascular access patency
urves. Number at risk indicated along curves. Cumulative AVF
atency was not different in the elderly versus non-elderly popula-
ions (P  .37). Dotted lines are used to indicate when patient
umbers were lower and the curves become imprecise.
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March 2011716 Jennings et alsored and were followed as pre-dialysis patients during the
study period. Seven patients received a kidney transplant
and were censored at that time. One of these patients was
awaiting a staged transposition; the other patient’s AVFs
were in use. Fourteen individuals were lost to follow-up at
8 to 58 months (mean, 32 months) and were censored at
that point. All of these patients had an access in use or, for
pre-dialysis patients, met the functional criteria outlined
Fig 2. A, Kaplan-Meier patient survival curve for patients 65 to
94 years of age. Number at risk indicated along curve. Dotted lines
are used to indicate when patient numbers were lower and the
curve becomes imprecise. B, Kaplan-Meier patient survival curves
for patients aged 65 to 94 years stratified into three 10-year
increments. Adjusting for diabetes, gender, and obesity, there was
a significant difference (P  .04) in survival between groups, with
Group 3 (the oldest patients) found to have shorter survival.
Number at risk indicated along curves. Dotted lines are used to
indicate when patient numbers were lower and the curves become
imprecise.previously. rThe incidence of steal syndrome requiring treatment
as not statistically different for patients older than 65 years
f age versus individuals aged 21 to 64 years. Steal syn-
rome warranted intervention in 15 (3.3%) patients 65
ears of age and in 24 (3.9%) patients aged 21 to 64 years of
ge. Of the patients 65 years of age, six individuals were
reated successfully by occlusion of enlarged side branches
educing overall access flow (five of these by coil occlusion
nd one surgically), two had arterial lesions treated by
alloon angioplasty, and seven were successfully treated by
banding procedure as described by Goel et al with our
ddition of real-time US flow monitoring.27 Two AVFs
ere ligated, and two of the salvaged accesses later failed.
here were no distal revascularization-interval ligation or
xillary artery inflow (proximalization) procedures in this
tudy group of older patients. Two patients with significant
ower extremity peripheral vascular disease required a femoral-
opliteal bypass using a polytetrafluoroethylene conduit
rior to thigh AVF construction. No patient had a graft
sed for vascular access during the study period.
During the study period, 156 patients died, 1.3 to 61
onths (mean, 20 months) after access creation. Eleven of
hese individuals died with a maturing AVF. None of these
eaths were related to the patient’s vascular access. These
atients’ AVFs were maturing satisfactorily and were con-
idered as patent in the data analysis. Secondary AVFs were
reated in all 58 patients evaluated with failed AVGs (n 
3) or failing AVGs (n  5), where mature and open
utflow veins were available for immediate post operative
annulation. Mean time to initial access cannulation was
.5 months (range, 0.75-6.0 months) not including the
ve patients with immediate access cannulation after cre-
tion of a secondary AVF.27 Patients with prolonged time
o access cannulation were those requiring staged transpo-
itions, interventions for maturation, staged lipectomy, or
ein elevation.28
Twenty-eight patients had AVFs that failed and were
ot salvaged during the study period. Among those indi-
iduals with a failed access, nine had a new successful AVF
reated, one changed to peritoneal dialysis, one received a
uccessful transplant, five were lost to follow-up, and the
est continued catheter-based dialysis treatments. Plans for
new access creation were in place for all catheter-based
atients, limited by general health issues, refusal of other
rocedures, or other issues. Eleven of these patients died
uring the follow-up period, none due to catheter sepsis.
ifty-eight patients had AVFs created prior to initiation of
ialysis; 14 of these patients had not started dialysis at the
nd of the study period.
ISCUSSION
Hemodialysis vascular access utilizing an AVF has been
idely recommended, demonstrating lower morbidity,
ortality, and cost than grafts and particularly cathet-
rs.5-10,29 With the population aging and the incidence of
enal failure in the elderly increasing, an important debate
as emerged as to whether this general vascular access
ecommendation holds true in older individuals. Age and
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Volume 53, Number 3 Jennings et al 717renal disease are among the independent predictors of
morbidity and mortality in older individuals.4 Both the
prevalence rate for dialysis and the median age of the
incident population have increased in theUnited States and
are expected to continue rising in future years, emphasizing
the importance of this health care discussion.2-4
Xue et al analyzed Medicare data for over 66,000
patients older than 66 years of age and found mortality risk
was greater in patients with initial vascular access of a
catheter or graft as opposed to an AVF.30 Successful autog-
enous vascular access outcomes in elderly patients have
been reported by several authors.11,12,14-17 We found
AVFs to have the same functional success in our older
patients as in younger individuals in our practice. Lok et al
reported similar findings.15 However, Richardson et al
reported lower AVF patency rates in elderly (70 years old)
versus non-elderly patients.18 Chan et al, analyzing the US
Renal Data System, also concluded that the potential ben-
efits derived from AVFs compared with AVGs and CVCs
may not apply universally for all elderly patients.13
Selecting the autogenous access operation with the
most likely successful outcome is important for all patients
and may be the key element in AVF success for elderly
patients. The many AVF options for creation of an autog-
enous access have been published in the National Kidney
Foundation Kidney Disease Outcomes Quality Initiative
guidelines, FistulaFirst, Society for Vascular Surgery® clin-
ical guidelines, and others.5,6,31 US vessel mapping before
fistula creation is another key element in success for both
elderly and younger patients.12,20 Simple AVFs are recom-
mended when possible, and distal sites chosen first when
feasible. However, several studies have noted a high pri-
mary failure rate for radiocephalic fistulas and poor out-
comes in all age groups.16,32 Other authors report success
with radiocephalic AVFs in older patients and the general
population, proposing that proper patient selection is key in
predicting successful outcomes.33,34 Konner, Lazarides,
and others reported mid-arm AVFs, such as perforating
vein fistulas and brachiocephalic access, are more likely to
be successful in older individuals.11,14,16 We observed that
many of our older patients have thinning and fragile skin
changes in the forearm consistent with chronic sun expo-
sure, in addition to poor forearm veins with multiple intra-
venous infusion and cannulation sites. These patients were
best served by construction of an AVF with upper arm
access sites. In older and more fragile patients, we most
often construct PRA-AVFs with venous outflow limited to
the upper arm cephalic vein, avoiding the additional bidi-
rectional forearm venous outflow added in many of our
general patient population PRA-AVFs.22 Patency rates for
females 65 years of age were lower than for males in this
study. Overall vessel size is smaller for females and may be
an explanation for this finding. Technical considerations in
obese individuals (both surgical and cannulation issues)
may be the cause of lower patency rates noted for these
patients.
Previous reports found older patients may be at greater
risk for steal syndrome with brachial artery inflow access.35 ise of the proximal radial artery for arterial inflow mini-
izes this risk, while offering adequate inflow for dialysis
ccess.22,36 We speculate that those chronic kidney disease
atients with severe arteriosclerotic disease may be less
ikely to survive into the older age groups, contributing, in
art, to our finding in this study that steal syndrome was
ot more common in older patients than in younger indi-
iduals65 years of age. Radial artery AVFs generally offer
ower access flows as opposed to brachial artery AVFs, and
his may also be important in the elderly population from a
ardiac standpoint.36,37
Our follow-up evaluation for elderly patients is similar
o that for the non-elderly with a goal of cannulating new
VFs within 4 to 6 weeks. Prompt and skilled AVF inter-
ention by fistulogram with angioplasty, when indicated, is
mportant for timely maturation and access maintenance in
substantial percentage of successful AVFs.
As expected, older patients receiving HD in the United
tates have a lower overall survival than non-dialysis pa-
ients and lower overall survival when compared with pa-
ients younger than 65 years of age.2 Jassal et al found life
xpectancy in elderly HD patients to have improved signif-
cantly during recent years adjusting for diabetes, gender,
nd other comorbidities.38 They reported the most recent
-, 3-, and 5-year survival rates among patients aged 65 to
4 years as 78.1%, 51.5%, and 33.5%, respectively, and for
hose patients75 years of age was 69%, 36.7%, and 20.3%,
espectively. Ellam et al reportedmedian patient survival for
lder patients from first recognition of Stage V chronic
idney disease to be 21months. Those individuals followed
y a nephrologist prior to initiating dialysis had a statisti-
ally longer survival (median, 32 months) as opposed to
hose individuals without a nephrologist (median, 15
onths).39 Survival data for patients 65 years of age in
ur study compared favorably with those of other reports.
Older patients may suffer with “geriatric syndromes”
haracterized by frailty, falls, and cognitive impairment and
re at higher risk for hospitalization, morbidity, mortality,
nd eventual nursing home placement.38,40,41 Frailty is
ommon among older dialysis patients and adds to mortal-
ty risk following initiation of dialysis. Although early ne-
hrology referral in older patients is thought to reduce
dverse chronic kidney disease outcomes, benefits of long-
erm dialysis in frail older patients remain controversial.40
urtagh et al found a survival advantage for patients over
5 years of age with end-stage renal disease who elected
ialysis as opposed to those who chose conservative treat-
ent, but the advantage was lost in patients with severe
omorbidities, particularly in patients with ischemic heart
isease.42 Yong et al found adverse symptoms and quality
f life to be similar for individuals treated with medical and
alliative care compared with patients receiving dialysis
herapy, pointing out that age should not be the sole factor
n deciding on renal replacement therapy, and that quality
f life should be taken into consideration as well as overall
urvival.41 Couchoud et al constructed a clinical scoring
ystem to predict 6-month prognosis in older patients
nitiating dialysis treatment.43 Factors that independently
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March 2011718 Jennings et alpredicted mortality at six months were low body mass
index, diabetes, congestive heart failure (Stages III-IV),
peripheral vascular disease (Stages III-IV), dysrhythmia,
active malignancy, severe behavioral disorder, impaired
mobility, and unplanned dialysis. In a study of 3702 nurs-
ing home residents, 58% of the individuals died within the
first 12 months of starting dialysis, and 29% had a decrease
in functional status during that period.44
The debate over best medical care for those end-stage
renal disease patients who are both frail and elderly with
severe comorbidities has not been settled and extends to
best medical treatment with or without dialysis, timing of
dialysis initiation, methods of HD access, and the role of
peritoneal dialysis. With the increasing burden of chronic
kidney disease on the Medicare system, this discussion
merges best patient care questions with those of increasing
Medicare costs. Hemodialysis is the most expensive mode
of renal replacement therapy, followed by peritoneal dialy-
sis and transplantation.45 For some patients, the addition of
HD may not prolong life and, in fact, may reduce the
quality of life.46
Study limitations include the retrospective analysis of
patient data and evaluation of a single surgeon experience.
Comorbidities such as heart disease were not included in
our analysis. Some frail and older patients may have re-
ceived renal replacement therapy by central venous catheter
access without referral for permanent dialysis access, and
therefore were not represented in this study. The study data
are from a complex referral vascular access practice with
over 50 dialysis units represented from several states in
addition to local patient referrals with failed access. Patients
were recorded as obese for our study from the medical
record diagnosis or physical examination, as body mass
index was not reliably available. We reported time to initial
cannulation, as complete data for each patient’s dialysis
treatments were not available.
CONCLUSIONS
AVFs are feasible and offer functional and timely he-
modialysis vascular access in older patients. There was no
difference in functional access outcomes for older patients
with subgroup age stratification. AVF patency rates were
not statistically different in the elderly and non-elderly
populations. Cumulative AVF patency for patients 65
years of age was 96.9% at 12 months and 94.6% at 24
months.
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Dr Anil Hingorani (Brooklyn, NY). I just had a question about
the comparison between the age groups that you had. Was the
distribution of the fistulas somewhat similar between the two? Be-
cause you had more forearm fistulas in the younger age group that
may have explained why your patency rates were somewhat similar.
Dr Jennings. We specifically targeted the upper arm sites in
many older patients for prompt cannulation and better skin condition
to withstand repeated cannulation. So I’m sure the distribution was
different. We did not record final access cannulation sites.
Dr Hingorani. And finally, most of those reinterventions,
were they balloon-assisted maturations?
Dr Jennings. We have a very skilled interventional colleague.
Almost all interventions were by balloon-angioplasty.
Dr Joe Naoum (Houston, Tex). In these elderly patients,
especially in those who have very frail and thin skin, is there a time
when you just abandon plans to create a fistula and decide to place
a graft instead? Is there a specific criteria that you tend to follow for
these patients?
Dr Jennings. There were no grafts placed in any of these
thousand-or-so patients during the time period studied. So we used
no grafts in any of those patients.
Cannulation of either a mature fistula or graft will still require
the needle passing through that same fragile skin. We find the skin
and soft tissue in older patients to be more substantial in the upper
arm. The cephalic vein is a little deeper, which gives you more soft
tissue to tolerate repeated cannulation.Dr Eugene Lee (Sacramento, Calif). Do you perform your
ranspositions in a one stage or two-staged procedure?
Dr Jennings. Generally, the vein size determines whether or
ot we stage or use primary transposition. If the vein is 4 mm or
maller, we use staged procedures. Brachial vein transpositions are
lmost all staged.
Dr Frank Padberg (Newark, NJ). You have for a long time
hampioned the proximal radial artery as a strategy to reduce the
ncidence of steal. How does that relate to these three patients that
eveloped steal in this series (ie, were any of the 3 radial-based AV
ccess)?
Dr Jennings.We found about 3%with steal syndrome and did
ot break it down according to inflow site. That’s a good com-
ent, and we should look at that. My impression is that radial
rtery inflow minimizes the risk of steal syndrome.
Dr Marc Mitchell (Jackson, Miss). I notice in your survival
ata, the older patients didn’t live much longer than a year or
wo. Wouldn’t they have been better off with just a catheter or
graft?
Dr Jennings.That is a very important question particularly for
ragile and older patients: Should they just have a catheter or graft?
’m not sure and that leads to a similar discussion: Are all fragile
nd older patients best served with dialysis, considering the risks,
omplications, and quality of life issues for these patients?
There are studies out now reviewing maximum medical ther-
py versus dialysis and suggesting that dialysis might not be the
est answer for every patient. Our paper didn’t address that, but it’s
ertainly an important question.
